News in Brief

Following extensive preclinical research, AudioCure Pharma has selected AC102 as its candidate for clinical development. Our next step will be to bring AC102 into the so-called formal preclinical stage of development, a prerequisite for the initiation of clinical...

We are very pleased to announce the start of our collaboration with Dr. Julian Hellmann-Regen, Head of the Clinical Neurobiology Laboratory at the Charité Universitätsmedizin, Berlin. Dr. Hellmann and his team will further investigate the molecular mode of action of...

We are happy to announce that Dr. Reimar Schlingensiepen has joined AudioCure as COO. Dr. Schlingensiepen is an experienced entrepreneur and manager for biotech, medtech and diagnostics companies. He offers his leadership expertise in the multiple fields of the...

AudioCure strives to protect its successful drug research by international patents. We are therefore very pleased, that the priority year of the Composition of Matter Patent „Fluorcarboline“ ended on September 29th. At the same time a supplemented version in the form...

AudioCure, in collaboration with Dr. Wernicke (Technical University of Applied Sciences, Wildau), and Dr. Enzensperger (University of Jena) has successfully tested the newly synthesized chemical entity AC102, a betacarboline, in an in vitro screening model. AC102 has...

The Technical University of Applied Sciences, Wildau biennially rewards outstanding achievements in both education and scientific research. In September, the Research Award 2013 went to the project: “Drug development for therapeutic and prophylactic treatments of...

AudioCure, met with federal minister and party head Dr. Philipp Rösler, on the occasion of a biotechnology function in Berlin. We were very pleased to be invited by the German Bundestag who aimed to bring an international group of investors together with highly...

High-Tech Gründerfonds and Business Angel Invest in AudioCure Pharma GmbH Drug Development AudioCure Pharma concentrates on the clinical development of drug candidates in neurological disease indications with a high unmet medical need. The lead candidate is a small...